[1]舒远路,杨翠先,张米,等.云南省HIV-1 B(B')、C亚型毒株的耐药突变分析[J].中国皮肤性病学杂志,2019,(05):547-552.[doi:10.13735/j.cjdv.1001-7089.201806126]
 SHU Yuanlu,YANG Cuixian,ZHANG Mi,et al.Analysis of Drug-resistance Mutations of HIV-1 B(B')and C Subtypes in Yunnan Province[J].The Chinese Journal of Dermatovenereology,2019,(05):547-552.[doi:10.13735/j.cjdv.1001-7089.201806126]
点击复制

云南省HIV-1 B(B')、C亚型毒株的耐药突变分析
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2019年05期
页码:
547-552
栏目:
性传播疾病
出版日期:
2019-04-01

文章信息/Info

Title:
Analysis of Drug-resistance Mutations of HIV-1 B(B')and C Subtypes in Yunnan Province
文章编号:
1001-7089(2019)05-0547-06
作者:
舒远路1杨翠先2张米2李健健2刘家法2杨壁珲2邓雪媚1董兴齐12
1. 大理大学,云南 大理 671000;2. 云南省传染病专科医院/艾滋病关爱中心,云南 昆明650301
Author(s):
SHU Yuanlu1YANG Cuixian2ZHANG Mi2LI Jianjian2LIU Jiafa2YANG Bihui2DENG Xuemei1DONG Xingqi12
(1.Dali University,Dali 671000,China;2.Yunnan Provincial Infections Disease Hospital/AIDS Care Center,Kunming 650301,China)
关键词:
艾滋病病毒1型亚型耐药突变
Keywords:
HIV-1SubtypeDrug resistance mutation
分类号:
R 593.32
DOI:
10.13735/j.cjdv.1001-7089.201806126
文献标志码:
B
摘要:
目的调查云南省艾滋病病毒1型B(B′)、C亚型毒株在ART失败后的耐药突变特征。方法对云南省15个地州定点医院2016年随访ART失败的HIV/AIDS患者的1 591份血浆样本,采用RT-PCR扩增HIV-1 pol 区蛋白酶和反转录酶基因,通过BLAST、jpHMM at GOBICS和MEGA6.06软件确证亚型,进行耐药突变位点的分析。结果共获得B(B′)、C亚型毒株分别为27例和63例,其中B(B′)、C亚型检测出发生耐药突变分别为22例和37例,耐药突变率为81.48%和58.73%。病毒载量在B(B′)、C亚型耐药突变的毒株间差异有统计学意义(P<0.05),未耐药突变的毒株间差异无统计学意义(P>0.05)。在所有检出耐药突变位点中,仅K103和A71突变率在两种亚型间差异有统计学意义(P<0.05)。在所有治疗方案中,仅TDF/3TC/EFV方案在两种亚型间的耐药突变率和病毒载量差异有统计学意义(P<0.05)。结论B(B′)、C亚型毒株ART失败后的耐药突变特征有差异,应加强两种亚型的耐药监测。
Abstract:
Objective To investigate characteristics of resistance mutations in HIV-1B (B′) and C subtypes after failure of antiretroviral therapy (ART) in Yunnan province.Methods From 2016, plasma samples were collected from 1 591 HIV/AIDS patients, who did not respond to ART, from 15 prefectures of Yunnan.Protease and reverse transcriptase gene in HIV-1 pol region were prepared and amplified using RT-PCR, followed by determination of HIV-1 subtypes and analysis of drug resistance mutations.ResultsTotal of 27 subtype B (B′) and 63 subtype C were identified.The resistance mutation rates of B(B′) and C subtypes were 81.48%(22/27)and 58.73%(37/63), respectively.Although viral load was similar between HIV-1 subtype B(B′) and C in strains without drug resistance mutations, it became significantly different between these two subtypes with drug resistance mutations (P<0.05).Among all drug resistance mutation sites, mutation frequencies of both K103 and A71 were significantly different between HIV-1 subtype B(B′) and C (P<0.05).Both viral load and drug resistance mutation rates were significantly different between HIV-1 subtype B(B′) and C in subjects with TDF/3TC/EFV therapy (P<0.05).ConclusionAfter failure of ART, characteristics of drug resistance mutations differ significantly between HIV-1 subtype B (B′) and C.It is necessary to strengthen the monitoring these two subtypes.

参考文献/References:


[1]杨绍敏, 李惠琴, 陈立力,等.云南省2008-2009年HIV-1病毒株亚型分布[J].中华流行病学杂志, 2012, 33(8):836-840.
[2] 李健健, 李惠琴, 李敬云,等.云南省2012-2014年HIV-1流行毒株亚型分布特征[J].中国艾滋病性病, 2016,22(3):145-149.
[3] 中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].4版.北京:人民卫生出版社,2016:47.
[4] Kantor R, Diero L, Delong A, et al.Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings[J].Clin Infect Dis, 2009, 49(3):454-462.
[5] 李敬云.HIV-1的耐药基因突变[J].中国艾滋病性病, 2010,16(2):195-197.
[6] 殷倩倩, 徐维四, 焦洋,等.HIV-1感染者血浆病毒RNA与全血前病毒DNA的比较[J].中国艾滋病性病, 2016,22(3):155-159.
[7] Iordanskiy S, Waltke M, Feng Y, et al.Subtype-associated differences in HIV-1 reverse transcription affect viral replication[J].Retrovirol, 2010, 7(1):85-102.
[8] 杨绍敏, 钟敏, 杨壁珲,等.云南省2008-2012年HIV-1耐药基因型检测情况[J].中国艾滋病性病, 2014,20(1):9-12.
[9] 蔡晓莉, 兰芸, 李俊彬,等.广东省不同感染途径HIV/AIDS病人HAART后HIV-1耐药性分析[J].中国艾滋病性病, 2015,21(5):369-372.
[10] 杨翠先.中国云南省HIV/AIDS患者基因变异与耐药的研究[D].重庆:第三军医大学,2015.
[11] Rhee SY, Liu T, Ravela J, et al.Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing[J].Antimicrob Agents Chemother, 2004, 48(8):3122-3126.
[12] David VDV, Wensing AM, Angarano G, et al.The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes[J].J Acquir Immune Defic Syndr, 2006, 41(3):352-360.
[13] Martínezcajas JL, Pantpai N, Klein MB, et al.Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence[J].Aids Rev, 2008, 10(4):212-223.
[14] 周海卫, 廖玲洁, 陈曦,等.CRF01_AE CRF07_BC和B′亚型HIV-1 pol基因及耐药特征分析[J].中国艾滋病性病, 2008, 14(3):213-216.
[15] Singh A, Sunpath H, Green TN, et al.Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options[J].J Acquir Immune Defic Syndr, 2011, 58(3):233-240.
[16] 张佳峰, 潘晓红, 郭志宏,等.2009-2011年浙江省HIV耐药警戒线调查[J].中华预防医学杂志, 2012, 46(6):519-523.
[17] Zhao B, Han X, Dai D, et al.New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China[J].Aids Res Hum Retroviruses, 2011, 27(10):1047-1053.
[18] Rhee SY, Taylor J, Fessel WJ, et al.HIV-1 Protease mutations and protease inhibitor cross-resistance[J].Antimicrob Agents Chemother, 2010, 54(10):4253-4261.

相似文献/References:

[1]李嘉彦,罗育武,毕超,等.性病门诊患者1 786例HPV基因亚型分析[J].中国皮肤性病学杂志,2014,(06):595.[doi:10.13735/j.cjdv.1001-7089.2014.0595]
 LI Jia-yan,LUO Yu-wu,BI Chao,et al.Analysis of the HPV Genetic Subtype in 1 786 STD Outpatients[J].The Chinese Journal of Dermatovenereology,2014,(05):595.[doi:10.13735/j.cjdv.1001-7089.2014.0595]
[2]刘佳,闫江舟,胡凯,等.河南省2014-2016年不同城市新确证HIV感染者的亚型分布和耐药传播情况分析[J].中国皮肤性病学杂志,2019,(04):437.[doi:10.13735/j.cjdv.1001-7089.201805160]
 LIU Jia,YAN Jiangzhou,HU Kai,et al.Analysis of Subtype and Drug Resistance in Newly Diagnosed HIV-infected Persons in Different Cities of He′nan Province from 2014 to 2016[J].The Chinese Journal of Dermatovenereology,2019,(05):437.[doi:10.13735/j.cjdv.1001-7089.201805160]

备注/Memo

备注/Memo:
[基金项目]云南省科技计划(重点新产品开发)(2016BC005)
[作者单位]1. 大理大学,云南 大理 671000;2. 云南省传染病专科医院/艾滋病关爱中心,云南 昆明650301
[通讯作者]董兴齐,E-mail:dongxq8001@126.com
更新日期/Last Update: 2019-04-15